Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
- Conditions
- DMD-Associated Dilated Cardiomyopathy
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Sardocor Corp.
- Target Recruit Count
- 12
- Registration Number
- NCT06224660
- Locations
- 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
- Conditions
- Heart Failure, DiastolicHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Sardocor Corp.
- Target Recruit Count
- 10
- Registration Number
- NCT06061549
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
- Conditions
- Congestive Heart FailureHeart Failure, SystolicHeart FailureHFrEF - Heart Failure With Reduced Ejection Fraction
- Interventions
- Biological: SRD-001Drug: Placebo
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Sardocor Corp.
- Target Recruit Count
- 57
- Registration Number
- NCT04703842
- Locations
- 🇺🇸
San Diego Cardiac Center, San Diego, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Washington University in Saint Louis, Saint Louis, Missouri, United States
News
Medera's SRD-002 Gene Therapy Advances in Phase 1/2a Trial for HFpEF
Medera Inc. has completed Cohort A (low-dose) and initiated dosing in Cohort B (high-dose) of the MUSIC-HFpEF trial, evaluating SRD-002 for heart failure with preserved ejection fraction (HFpEF).